Vinorelbine 50mg/5mL
| Product Overview | |
| Generic Name | Vinorelbine 50mg/5mL |
| Brand Name(s) | Navelbine |
| Form | Injection/IV solution |
| Strength | 50mg/5mL |
| Therapeutic Class | Vinca alkaloid analogue, antineoplastic agent |
| ATC Code | L01CA04 |
| Manufacturing & Regulatory | |
| Manufacturer | Pierre Fabre Pharma, Flroencia |
| Country | France, India |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Not publicly disclosed |
| COFEPRIS | Pending |
| Free Sale Certificate | Available from supplier on request |
| Logistics & Export | |
| MOQ | 5 |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Upon Request, not publicly posted |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Vinorelbine is indicated for the treatment of non-small-cell lung cancer (NSCLC) and in some jurisdictions for metastatic breast cancer.
